Sex steroid activity inhibitors

A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of an estrogen activity inhibitor of the following formula:

• ##STR157## wherein the dotted line is optional double bond;
• wherein R.sub.5 and R.sub.6 are independently hydrogen, hydroxyl or a moiety which is converted to hydroxyl in vivo, but are not simultaneously hydrogen and are not simultaneously at positions 3 and 12;
• wherein Z is a bivalent ring closing moiety;
• wherein R.sup.100 is a bivalent moiety which distances L from the B-ring by 4-10 intervening atoms;
• wherein L is a bivalent or trivalent polar moiety selected from the group consisting of --CO--, --SO--, --CON<, --N<
• and --SON<;
• wherein G.sup.1 is either absent or selected from the group consisting of hydrogen, a C.sub.1 to C.sub.5 hydrocarbon, a saturated or unsaturated C.sub.5 to C.sub.7 cycloalkyl, a bivalent moiety which joins G.sup.2 and L to form a 5- to 7-membered heterocyclic ring, and halo-substituted derivatives of the foregoing;
• wherein G.sup.2 is either absent or selected from the group consisting ft hydrogen, a C.sub.1 to C.sub.5 hydrocarbon, a substituted or unsubstituted C.sub.5 to C.sub.7 cycloalkyl, a bivalent moiety which joins G.sup.1 and L to form a 5- to 7-membered heterocyclic ring and halo-substituted derivatives of the foregoing;
• and
• wherein G.sup.3 is a lower hydrocarbon.